| 查看: 565 | 回复: 3 | |||
[交流]
求高人帮翻译一段说明书 急~
|
|||
|
1 General Responding patients may not experience an improvement in performance status on therapy and may experience worsening. The relationship between changes in performance status, response to therapy, and treatment-related side effects has not been established. 2 Cutaneous Localized erythema of the extremities with edema followed by desquamation has been observed. In case of severe skin toxicity, an adjustment in dosage is recommended [see Dose Adjustments During Treatment (2.7)]. The discontinuation rate due to skin toxicity was 1.6% (15/965) for metastatic breast cancer patients. Among 92 breast cancer patients premedicated with 3-day corticosteroids, there were no cases of severe skin toxicity reported and no patient discontinued TAXOTERE due to skin toxicity. 3 Fluid Retention Severe fluid retention has been reported following TAXOTERE therapy [see Boxed Warning, Premedication Regimen (2.6)]. Patients should be premedicated with oral corticosteroids prior to each TAXOTERE administration to reduce the incidence and severity of fluid retention [see Premedication Regimen (2.6)]. Patients with pre-existing effusions should be closely monitored from the first dose for the possible exacerbation of the effusions. When fluid retention occurs, peripheral edema usually starts in the lower extremities and may become generalized with a median weight gain of 2 kg. Among 92 breast cancer patients premedicated with 3-day corticosteroids, moderate fluid retention occurred in 27.2% and severe fluid retention in 6.5%. The median cumulative dose to onset of moderate or severe fluid retention was 819 mg/m2. 9.8% (9/92) of patients discontinued treatment due to fluid retention: 4 patients discontinued with severe fluid retention; the remaining 5 had mild or moderate fluid retention. The median cumulative dose to treatment discontinuation due to fluid retention was 1021 mg/m2. Fluid retention was completely, but sometimes slowly, reversible with a median of 16 weeks from the last infusion of TAXOTERE to resolution (range: 0 to 42+ weeks). Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). 4 Neurologic Severe neurosensory symptoms (paresthesia, dysesthesia, pain) were observed in 5.5% (53/965) of metastatic breast cancer patients, and resulted in treatment discontinuation in 6.1%. When these symptoms occur, dosage must be adjusted. If symptoms persist, treatment should be discontinued [see Dose Adjustments During Treatment (2.7)]. Patients who experienced neurotoxicity in clinical trials and for whom follow-up information on the complete resolution of the event was available had spontaneous reversal of symptoms with a median of 9 weeks from onset (range: 0 to 106 weeks). Severe peripheral motor neuropathy mainly manifested as distal extremity weakness occurred in 4.4% (42/965). 5 Asthenia Severe asthenia has been reported in 14.9% (144/965) of metastatic breast cancer patients but has led to treatment discontinuation in only 1.8%. Symptoms of fatigue and weakness may last a few days up to several weeks and may be associated with deterioration of performance status in patients with progressive disease. 6. ADVERSE REACTIONS Adverse reactions are described for TAXOTERE according to indication. 6.1 Clinical Trial Experience • Breast Cancer Monotherapy with TAXOTERE for locally advanced or metastatic breast cancer after failure of prior chemotherapy TAXOTERE 100 mg/m2: Adverse drug reactions occurring in at least 5% of patients are compared for three populations who received TAXOTERE administered at 100 mg/m2 as a 1-hour infusion every 3 weeks: 2045 patients with various tumor types and normal baseline liver function tests; the subset of 965 patients with locally advanced or metastatic breast cancer, both previously treated and untreated with chemotherapy, who had normal baseline liver function tests; and an additional 61 patients with various tumor types who had abnormal liver function tests at baseline. These reactions were described using COSTART terms and were considered possibly or probably related to TAXOTERE. At least 95% of these patients did not receive hematopoietic support. The safety profile is generally similar in patients receiving TAXOTERE for the treatment of breast cancer and in patients with other tumor types (See Table 4). |
回复此楼» 猜你喜欢
0703 物理化学调剂
已经有5人回复
-
化学工程321分求调剂
已经有7人回复
-
0703化学调剂 290分有科研经历，论文在投
已经有7人回复
-
308求调剂
已经有3人回复
-
本人考085602 化学工程 专硕
已经有10人回复
-
焦虑
已经有9人回复
-
0856求调剂
已经有3人回复
-
283求调剂
已经有11人回复
-
深圳大学硕士招生（2026秋，传感器方向，仅录取第一志愿）
已经有8人回复
-
0703化学调剂
已经有7人回复
» 抢金币啦！回帖就可以得到:
-
崂山国家实验室博士后岗位招聘
+2/206
-
深圳技术大学集成电路与光电芯片学院郝俊杰课题组诚聘博士后、研究助理、访问学生
+2/138
-
专业技术开发及第三方检测
+1/87
-
福建师范大学招收2026年化学、材料硕士3-4名
+1/82
-
博士后出站经验请教
+1/79
-
【武汉高校】【新能源材料与器件课题组】 招收优秀硕士调剂生！！！
+5/50
-
天津工业大学航空航天博士招生
+1/36
-
【沈阳农业大学机械专硕调剂】
+2/30
-
厦门大学航空航天学院智能制造课题组招2026年申请审核制博士生1名
+1/22
-
福建师范大学化学与材料学院杜克钊团队博士/硕士招生
+1/15
-
（国家级人才团队 ）医药与生物技术方向 “申请-考核”制博士研究生招生
+1/8
-
食品科学与工程083200-297分
+1/8
-
重庆大学药学院闫海龙课题组拟招收2026年申请考核制博士研究生数名
+1/7
-
【第三轮招生，31号截止】澳科大诚招2026秋全奖博士研究生（纳米医学/生物材料方向）
+1/6
-
深圳大学蔡兴科课题组博士后及研究助理招聘
+1/6
-
福建师范大学国家级人才团队招收2026年调剂的硕士研究生若干名
+1/5
-
高校招聘
+1/3
-
国家杰青低维材料与器件力学团队2026年招收博士研究生
+1/2
-
欢迎报考浙江工业大学埃克塞特联合学院硕士研究生
+1/1
-
2026年浙江清华长三角研究院智慧能源中心招聘博士后-电气方向
+1/1
3楼2011-04-06 14:46:32
这么长 4楼2011-04-06 15:01:20
简单回复
Mally892楼
2011-04-01 16:57
回复
suibowen2010(金币+1, 翻译EPI+1): 嘿嘿 没有办法啊 任务...看的不是很到位 很多话不知道怎么说 所以才来这求助高人啊~ 2011-04-01 19:48:04
ringzhu(翻译EPI-1): 无效应助 2011-04-06 12:41:16
哇！ringzhu(翻译EPI-1): 无效应助 2011-04-06 12:41:16
